Skip to main content

ArriVent BioPharma, Inc.

corporate_fare Company Profile

ArriVent BioPharma, Inc.

AVBP·NASDAQ·Life Sciences·CIK 0001868279

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on finding, developing, and selling distinct medicines for cancer patients with unmet medical needs. The company uses its team's drug development experience to advance its main product candidate, firmonertinib, and a pipeline of new treatments, including next-generation antibody drug conjugates like ARR-217 (MRG007), through approval and commercialization for cancer patients, initially focusing on solid tumors. Firmonertinib is currently in multiple clinical trials for various epidermal growth factor receptor (EGFR) mutations (EGFRm) in non-small cell lung cancer (NSCLC). ArriVent is conducting a pivotal Phase 3 clinical trial of firmonertinib in treatment-naive, or first-line, patients with locally advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations. It is also conducting another pivotal Phase 3 clinical trial of firmonertinib in first-line patients with locally advanced or metastatic EGFRm NSCLC with P-loop and-alpha-c-helix compressing (PACC) mutations. Additionally, a Phase 1 clinical trial for ARR-217 is underway in patients with unresectable locally advanced or metastatic solid tumors. The U.S. Food and Drug Administration (FDA) granted firmonertinib Breakthrough Therapy Designation (BTD) for first-line EGFRm NSCLC with exon 20 insertion in October 2023. Firmonertinib also received Orphan Drug Designation for treating NSCLC with EGFRm or human epidermal growth factor receptor 2 (HER2) mutations or human epidermal growth factor receptor 4 (HER4) mutations in February 2024.

ArriVent BioPharma, Inc. (NASDAQ:AVBP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for AVBP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for AVBP spans 10-Q, 8-K, 424B5, DEF 14A.

Recent high-impact activity:

  • ArriVent 10-Q: $40.3M Q3 Loss, $393.2M Cash to Mid-2028, Firmonertinib Patent Claims Confirmed
  • ArriVent Posts $40.3M Q3 Loss, $393.2M Cash to Mid-2028; R&D Chief Lutzker to Retire
  • ArriVent Posts $40.3M Q3 Loss, $393M Cash Through Mid-2028 as FURVENT Review Continues
  • ArriVent's ARR-217 ADC Shows 44.8% ORR in Late-Line CRC at ESMO 2026
  • ArriVent Doses First Patient in Phase 1 Trial of Dual-Target ADC ARR-002

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$166.31M
Diluted EPS
-$4.32
Op. Cash Flow
-$160.59M
Operating Income
-$177.53M
Cash & Equivalents
$45.54M
Debt / Equity
0.00×
Shares Outstanding
42.45M sh
Source: 10-K · filed 2026-03-05 · accession 0001104659-26-024127

Short Interest & Short Volume

3.43 days to cover

FINRA reported short interest of 5,797,018 shares in AVBP as of the October 30, 2026 settlement, a 14.8% decrease from the prior period — about 3.4 days to cover at its recent average daily volume. On November 20, 2026, 52.2% of AVBP volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,797,018 shares as of October 30, 2026
Change vs prior period▼ 14.8%
Days to cover3.43 at avg daily volume of 1,689,459
Daily short volume (FINRA facilities)52.2% of 374,072 shares on November 20, 2026
5-day average short volume40.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$10.52
52-week range · as of 2026-11-09 $10.52 – $35.83
Market cap
$544.13M
Volume
1.1M (0.8× avg)
3-mo avg 1.4M
Live data · 2026-11-22 07:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AVBP - Latest Insights

AVBP
Nov 09, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.16
Real-time Price: $10.52 info
Change: -$3.64 (-26%) info
Market Cap: $544.127M info
AVBP
Nov 09, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.16
Real-time Price: $10.52 info
Change: -$3.64 (-26%) info
Market Cap: $544.127M info
AVBP
Nov 09, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $14.16
Real-time Price: $10.52 info
Change: -$3.64 (-26%) info
Market Cap: $544.127M info
AVBP
Oct 26, 2026, 6:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $23.30
Real-time Price: $10.52 info
Change: -$12.78 (-55%) info
Market Cap: $544.127M info
AVBP
Oct 12, 2026, 5:29 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $16.46
Real-time Price: $10.52 info
Change: -$5.94 (-36%) info
Market Cap: $544.127M info
AVBP
Oct 06, 2026, 8:07 AM EDT
Filing Type: 8-K
Importance Score:
9
Updated Oct 6, 11:54 AM ET — ArriVent shares plunged 54% to $13, on pace for its largest single-day decline on record.
Price at Filing: $28.70
Real-time Price: $10.52 info
Change: -$18.18 (-63%) info
Market Cap: $544.127M info
AVBP
Oct 06, 2026, 8:00 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $28.70
Real-time Price: $10.52 info
Change: -$18.18 (-63%) info
Market Cap: $544.127M info
AVBP
Aug 12, 2026, 4:20 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $31.46
Real-time Price: $10.52 info
Change: -$20.94 (-67%) info
Market Cap: $544.127M info
AVBP
Aug 12, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $31.46
Real-time Price: $10.52 info
Change: -$20.94 (-67%) info
Market Cap: $544.127M info
AVBP
Aug 12, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $31.46
Real-time Price: $10.52 info
Change: -$20.94 (-67%) info
Market Cap: $544.127M info
AVBP
May 11, 2026, 4:43 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $29.02
Real-time Price: $10.52 info
Change: -$18.50 (-64%) info
Market Cap: $544.127M info
AVBP
May 11, 2026, 4:41 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $29.02
Real-time Price: $10.52 info
Change: -$18.50 (-64%) info
Market Cap: $544.127M info
AVBP
May 11, 2026, 4:11 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $29.02
Real-time Price: $10.52 info
Change: -$18.50 (-64%) info
Market Cap: $544.127M info
AVBP
May 11, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $29.02
Real-time Price: $10.52 info
Change: -$18.50 (-64%) info
Market Cap: $544.127M info
AVBP
May 07, 2026, 8:05 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $29.62
Real-time Price: $10.52 info
Change: -$19.10 (-64%) info
Market Cap: $544.127M info
AVBP
Apr 28, 2026, 4:08 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $30.04
Real-time Price: $10.52 info
Change: -$19.52 (-65%) info
Market Cap: $544.127M info
AVBP
Mar 17, 2026, 5:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $24.01
Real-time Price: $10.52 info
Change: -$13.49 (-56%) info
Market Cap: $544.127M info
AVBP
Mar 05, 2026, 4:25 PM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $24.80
Real-time Price: $10.52 info
Change: -$14.28 (-58%) info
Market Cap: $544.127M info
AVBP
Mar 05, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $24.50
Real-time Price: $10.52 info
Change: -$13.98 (-57%) info
Market Cap: $544.127M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets